Ģý North America Presents New Insights Related to COVID-19 and Dialysis Innovations at Kidney Week 2020
65 Abstracts Offered at American Society of NephrologyĢýs Reimagined Conference
WALTHAM, Mass. Ģý Oct 22, 2020 Ģý(FMCNA), the nationĢýs leading provider of kidney care products and services, today announced the presentation of 65 company-affiliated abstracts at the American Society of Nephrology (ASN) Annual Conference, which runs virtually from Oct. 22-25, 2020. These publications include new insights related to COVID-19, phosphate binders, a new dialysis system under development, and new software to attain relative blood volume.
In addition to the abstracts presented online, Dr. Jeffrey Hymes, SVP of Scientific and Clinical Affairs at FMCNA and Chief Medical Officer at Fresenius Kidney Care, will discuss the companyĢýs pandemic response during the conferenceĢýs clinical practice session ĢýCOVID-19: The Pandemic and the Outpatient Dialysis SettingĢý on Oct. 25 at 10:30 a.m. ET.
ĢýThe research abstracts presented this year demonstrate our approach to confronting the pandemic, along with new solutions that aim to improve the treatment of people with kidney failure,Ģý said Dr. Robert Kossmann, Chief Medical Officer for FMCNA. ĢýThese insights showcase the breadth and depth of our research team, highlighting the many ways that we are working to advance kidney care.Ģý
The annual symposium, reimagined virtually for 2020, is one of the most influential gatherings of kidney professionals in the world. Some of the abstracts being presented by Ģý, and now available online as part of ASNĢýs Kidney Week 2020 Reimagined, include:
- .The results presented in this abstract highlight changes in vital signs, body weight, and inflammatory markers that appear to be defining the onset of COVID-19 in hemodialysis (HD) patients.
- This abstract details how surveillance of the trends in fever and respiratory illness have utility for early identification of areas with a COVID-19 outbreak in the dialysis population.
- .Results from a pilot trial characterize the behavior of new software that provides real-time UFR adjustments throughout a dialysis treatment to steer the patientĢýs RBV curve into certain targets.
- .A low-cost optical sensor detects white blood cells in spent peritoneal dialysate without alteration of the existing drain line. This technology helps to detect changes heralding peritonitis.
- The new Optiflux EnexaTMdialyzer containing a fluorinated polyurethane surface modifying macromolecule (Endexo™) was well tolerated in a clinical study including 664 HD treatments in end stage renal disease patients.
- In HD patients treated with sevelamer at baseline, patients switched to Velphoro had a 15% lower rate of hospitalizations compared to patients switched to non-Velphoro phosphate binders.
Ģý Ģý North America
Ģý North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Ģý North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the worldĢýs largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. For more information, visit the FMCNA website at.
